Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) invites you to our presentation at the Sidoti Micro-cap Virtual Conference on August 15, 2:30-3:00 pm ET in Track 3.      Douglas Losordo, MD, Chief Medical Officer of Cadrenal Therapeutics, will provide an overview of our progress in developing our lead candidate, tecarfarin.      With FDA orphan drug and fast-track designations, tecarfarin is a novel oral vitamin K antagonist designed to meet critical unmet chronic anticoagulation needs in patients with implanted cardiac devices and rare cardiovascular conditions.      We look forward to discussing our clinical milestones and business development strategy with investor participants.     https://lnkd.in/g5yPtHDr    #CadrenalTherapeutics #Anticoagulation #Tecarfarin #CardiovascularHealth #PharmaInnovation #Biotech #OrphanDrug #FastTrack #Healthcare #SidotiConference #ClinicalTrials #CVKD #LVAD

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) invites you to our presentation at the Sidoti Micro-cap Virtual Conference on August 15, 2:30-3:00 pm ET in Track 3.      Douglas Losordo, MD, Chief Medical Officer of Cadrenal Therapeutics, will provide an overview of our progress in developing our lead candidate, tecarfarin.      With FDA orphan drug and fast-track designations, tecarfarin is a novel oral vitamin K antagonist designed to meet critical unmet chronic anticoagulation needs in patients with implanted cardiac devices and rare cardiovascular conditions.      We look forward to discussing our clinical milestones and business development strategy with investor participants.     https://lnkd.in/eFsv-hQB    #CadrenalTherapeutics #Anticoagulation #Tecarfarin #CardiovascularHealth #PharmaInnovation #Biotech #OrphanDrug #FastTrack #Healthcare #SidotiConference #ClinicalTrials #CVKD #LVAD

Amylyx Pharmaceuticals completes enrolment in Wolfram syndrome therapy trial. In November 2020, the US FDA granted orphan drug designation to AMX0035 to treat WS. The open-label proof of biology study enrolled a total of 12 adult subjects with initial data expected in the second half of 2024. HELIOS is designed to assess AMX0035’s impact on tolerability and safety apart from various aspects of health in individuals with WS. They include endocrinological, neurological, and ophthalmologic functions. An oral medication, AMX0035 combines sodium phenylbutyrate and taurursodiol. It is already approved in the US under the brand name RELYVRIO for treating amyotrophic lateral sclerosis (ALS) in adults and as ALBRIOZA in Canada with conditions for the same indication. https://lnkd.in/eGEjzz5N

Otsuka and Lundbeck’s Schizophrenia Treatment Gains EC Approval https://lnkd.in/gAV_ma7s Lundbeck, which has offices in Bothell, Washington, announced the European Commission approved Otsuka Pharmaceutical Europe and H Lundbeck’s Abilify Maintena 720mg/960mg (aripiprazole) for schizophrenia treatment. The treatment is the first introduction of a once-every-two-month long-acting injectable in the European Union for this indication. According to Dr. Johan Luthman, Lundbeck research and development executive vice president and head, “Specifically designed for adult patients with schizophrenia who have been stabilised with aripiprazole, this treatment aims to increase patient adherence and convenience, contributing to the careful and comprehensive management of this chronic condition.” The post Otsuka and Lundbeck’s Schizophrenia Treatment Gains EC Approval appeared first on Life Science Washington . Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks

MIRA Pharmaceuticals KETAMIR-2 shines in preclinical studies, outperforming existing pain treatments with improved safety! 💊 A promising leap in inflammation and pain management therapy. Know complete story - https://lnkd.in/djh6GaWV #KETAMIR2 #PainManagement #InnovativeTherapy #PharmaBreakthrough

Resmetirom (REZDIFFRA): The First Approved Drug for NASH | https://lnkd.in/gNRgKHu2 -2023 Molecule of the Year Nominee (#9/10)- On Mar. 14th, 2024, resmetirom (REZDIFFRA™) became the first and only medicine approved by the FDA for the treatment of NASH (non-alcoholic steatohepatitis, aka MASH). Resmetirom, an oral, liver-targeting, once-daily THR-β-selective agonist originally discovered at Roche Nutley, was first highlighted as a Molecule of the Month in Dec. 2022. Now, with the FDA’s accelerated approval thanks to Madrigal Pharmaceuticals's continued development, this 2023 Molecule of the Year nominee reflects a historic milestone for liver drug discovery. This full article reviews how the molecule works, how it was discovered, and why it’s a big deal: https://lnkd.in/gNRgKHu2

RESMETIROM (REZDIFFRA™): THE FIRST APPROVED DRUG FOR NASH On Mar. 14th, 2024, resmetirom (REZDIFFRA™) became the first and only medicine approved by the FDA for the treatment of NASH (non-alcoholic steatohepatitis, aka MASH). https://lnkd.in/dZadsi4b NASH is a result of the progression of nonalcoholic fatty liver disease where liver inflammation, over time, can lead to liver scarring and liver dysfunction. NASH is often associated with other health problems such as high blood pressure and type 2 diabetes. By at least one estimate, approximately 6-8 million people in the U.S. have NASH with moderate to advanced liver scarring, with that number expected to increase. Resmetirom (Rezdiffra™) is a partial activator of a thyroid hormone receptor; activation of this receptor by Rezdiffra in the liver reduces liver fat accumulation. Resmetirom is an oral, liver-targeting, once-daily THR-β-selective agonist originally discovered at Roche Nutley, was first highlighted as a Molecule of the Month in Dec. 2022. Now, with the FDA’s accelerated approval, this 2023 Molecule of the Year nominee reflects a historic milestone for liver drug discovery. This article reviews how the molecule works, how it was discovered, and why it’s a big deal.

AMX0035 Shows Promise for Treating Wolfram Syndrome 🌟🧬 Amylyx Pharmaceuticals' AMX0035 demonstrates potential in treating Wolfram syndrome, a rare neurodegenerative disease. Initial clinical data reveal improvements in patient outcomes, marking a significant step forward in addressing this debilitating condition. Continued research aims to validate these findings and expand therapeutic options for Wolfram syndrome patients. To read the full news, visit 👉 https://lnkd.in/dfKyj8uD Stay updated with the latest in pharmaceutical advancements at https://lnkd.in/dKhZfHxi #PharmaNow #pharmanews #healthcareinnovation #globalpharma #wolframsyndrome #rarediseases #clinicaltrials #AmylyxPharmaceuticals

I'm pleased to announce the addition of Ritchie Patton, MBA, Manager, Regulatory Strategy, MMS Holdings, to the agenda for the 4th Annual Psychedelic Therapeutics Conference, taking place in Boston on May 23-24, 2024. FDA requires that potential for nonmedical use must be assessed for any investigational new drug that has CNS activity. Current regulatory recommendations may lack the nuance required to appropriately evaluate drugs with novel or previously unrecognized drivers of nonmedical use. Capturing and assessing the experiences, subjective effects, and/or changes in consciousness that may drive additional use for psychedelic drugs poses a challenge for the industry as a whole. This session will outline the requirements for an abuse potential summary in a marketing application, and address the unique challenges associated with assessing the nonmedical use (i.e., abuse or misuse) potential of psychedelic drugs. Learn more about this event by visiting https://lnkd.in/eM5iiPn. #psychedelics #psychedelicresearch #psychedelictherapy #boston